DOMA Perpetual Capital Management announced it has nominated three candidates for the board of directors at Pacira BioSciences Inc. (NASDAQ: PCRX), according to a press release statement.

The investment firm, which holds approximately 7.1% of Pacira's outstanding shares, nominated Christopher Dennis, Oliver Benton Curtis and Eric de Armas as director candidates. DOMA filed a preliminary proxy statement with the Securities and Exchange Commission to solicit votes for the election of its slate at the 2026 annual meeting of stockholders.

Dennis is described as a physician executive and board-certified psychiatrist with over 25 years of leadership experience in behavioral health and substance use disorders. Curtis is a former federal prosecutor who advises on regulatory enforcement and internal investigations. De Armas serves as CFO and CCO of DOMA Perpetual with over two decades of financial industry experience.

DOMA stated that Pacira's stock has declined 56% over the last decade and 68% over the last five years. The firm called for CEO Frank Lee to be replaced and for the board to conduct a sale process of the business.

The press release states that DOMA believes the board should engage bankers to proceed with a sale of the company and discontinue future acquisitions. DOMA described EXPAREL as "the only non-opioid pain medication for use in the surgical setting in the United States."

As of the filing date, DOMA LO Master directly owns 1,965,775 shares of Pacira common stock, while the John Templeton Foundation directly owns 812,019 shares, according to the disclosure.

DOMA Perpetual Capital Management is an asset management firm based in Miami, Florida that employs what it describes as an opportunistic, fundamentals-based investment strategy.